149 related articles for article (PubMed ID: 25287483)
1. Inhibition of hepatitis C entry: too soon to dismiss while many are still being denied treatment.
Uprichard SL; Sainz B
Gut; 2015 Apr; 64(4):690-1. PubMed ID: 25287483
[No Abstract] [Full Text] [Related]
2. Viral entry inhibition: too late for hepatitis C, but promising for other viral infections.
Pawlotsky JM
Gut; 2015 Mar; 64(3):362-4. PubMed ID: 25098973
[No Abstract] [Full Text] [Related]
3. Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors.
Mittapalli GK; Jackson A; Zhao F; Lee H; Chow S; McKelvy J; Wong-Staal F; Macdonald JE
Bioorg Med Chem Lett; 2011 Nov; 21(22):6852-5. PubMed ID: 21978675
[TBL] [Abstract][Full Text] [Related]
4. Identification of a series of 1,3,4-trisubstituted pyrazoles as novel hepatitis C virus entry inhibitors.
Hwang JY; Kim HY; Park DS; Choi J; Baek SM; Kim K; Kim S; Seong S; Choi I; Lee HG; Windisch MP; Lee J
Bioorg Med Chem Lett; 2013 Dec; 23(23):6467-73. PubMed ID: 24125883
[TBL] [Abstract][Full Text] [Related]
5. Curcumin against hepatitis C virus infection: spicing up antiviral therapies with 'nutraceuticals'?
Pécheur EI
Gut; 2014 Jul; 63(7):1035-7. PubMed ID: 24092864
[No Abstract] [Full Text] [Related]
6. Entry inhibitors and future treatment of hepatitis C.
Fofana I; Jilg N; Chung RT; Baumert TF
Antiviral Res; 2014 Apr; 104():136-42. PubMed ID: 24525381
[TBL] [Abstract][Full Text] [Related]
7. ["Entry inhibitors" prevent virus access to the cell]].
Fessler B
MMW Fortschr Med; 2015 Mar; 157 Suppl 1():86. PubMed ID: 26012995
[No Abstract] [Full Text] [Related]
8. Entry inhibitors: New advances in HCV treatment.
Qian XJ; Zhu YZ; Zhao P; Qi ZT
Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
[TBL] [Abstract][Full Text] [Related]
9. How does interferon inhibit HCV cell entry?
Jones M; Owen JS
Gut; 2008 May; 57(5):573-4. PubMed ID: 18408099
[No Abstract] [Full Text] [Related]
10. Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry Inhibitors
Koutsoudakis G; Paris de León A; Herrera C; Dorner M; Pérez-Vilaró G; Lyonnais S; Grijalvo S; Eritja R; Meyerhans A; Mirambeau G; Díez J
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193659
[TBL] [Abstract][Full Text] [Related]
11. Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner.
Lee M; Yang J; Park S; Jo E; Kim HY; Bae YS; Windisch MP
Antiviral Res; 2016 Aug; 132():287-95. PubMed ID: 27387825
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus entry.
Zeisel MB; Felmlee DJ; Baumert TF
Curr Top Microbiol Immunol; 2013; 369():87-112. PubMed ID: 23463198
[TBL] [Abstract][Full Text] [Related]
13. (4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry.
Chung CY; Liu CH; Wang GH; Jassey A; Li CL; Chen L; Yen MH; Lin CC; Lin LT
Sci Rep; 2016 Jul; 6():29969. PubMed ID: 27426693
[TBL] [Abstract][Full Text] [Related]
14. Gumming up the works: DNA polymers as HCV entry inhibitors.
Counihan NA; Lindenbach BD
Gastroenterology; 2009 Aug; 137(2):427-30. PubMed ID: 19563837
[No Abstract] [Full Text] [Related]
15. Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds.
Tai CJ; Li CL; Tai CJ; Wang CK; Lin LT
J Vis Exp; 2015 Oct; (105):e53124. PubMed ID: 26555014
[TBL] [Abstract][Full Text] [Related]
16. Introduction to hepatitis C virus (HCV) therapies special thematic issue.
Meanwell NA; Watkins WJ
J Med Chem; 2014 Mar; 57(5):1625-6. PubMed ID: 24484173
[No Abstract] [Full Text] [Related]
17. Treating hepatitis B virus/hepatitis C virus coinfected patients with direct-acting hepatitis C virus antivirals only is not safe.
Ozaras R; Sunbul M; Parlak M; Bodur H; Leblebicioglu H
Hepatology; 2016 Nov; 64(5):1825-1827. PubMed ID: 27043022
[No Abstract] [Full Text] [Related]
18. Hepatitis C virus (HCV) therapies special thematic issue: call for papers.
Georg GI; Wang S
J Med Chem; 2013 Jan; 56(2):387. PubMed ID: 23294104
[No Abstract] [Full Text] [Related]
19. [Predictive factors of response to Direct Acting Antivirals therapy Drug resistance hepatitis C virus].
Suda G; Yamasaki K; Sakamoto N
Nihon Rinsho; 2015 Dec; 73 Suppl 9():189-92. PubMed ID: 26845928
[No Abstract] [Full Text] [Related]
20. [Expert advices for evaluating clinical trials of direct-acting antiviral agents for hepatitis C].
Research Group for New Drug's Clinical Evalutaion of Critical Diseases and Platform Construction of Integrated Technology
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):161-4. PubMed ID: 27095756
[No Abstract] [Full Text] [Related]
[Next] [New Search]
